In tumors enriched for HER2, MLR might indicate resistance to targeted treatments like trastuzumab, whereas in triple-negative breast cancer, marked by increased immunogenicity, a high MLR correlates with greater tumor aggressiveness and reduced survival. Here, ERBB2 is linked to neoplasm.